Jerome J Schentag

The Official Site

This information site is dedicated to the many colleagues, students, postdocs and graduate students who listened patiently to my monologues and discussions and without whose feedback, few of these inventions would have gotten this far.

Everything to follow is a work in progress. The stories are interesting, the challenges are many. Some inventions make more progress than others.

More Information:

Google Scholar

Research Gate

Linkedin Site

Justia: Patents List

Current Patents
Organized by Patent Platform

Contact Information

Biographical Journey from Academia to Inventor and Commercialization

Professor Jerome J. Schentag, Inventor & Chief Executive Officer of TheraSyn Companies and Emeritus Professor of Pharmacy at the State University of NY (SUNY) in Buffalo. Prof Schentag has 40+ years of US and Global Clinical Trial expertise in Infectious Diseases, Critical Care, Sepsis and Metabolic Syndrome.

He is also the inventor of the SmartPill, a medical device for diagnosis of GI tract currently marketed worldwide. SmartPill is the predicate device for the characterization of Gastric emptying, small bowel motility and the unique signaling properties of the ileal Brake. He is the co-inventor of Brake™, the first oral mimetic of RYGB (Gastric Bypass Surgery) and its associated improvement of Type 2 Diabetes and Metabolic Syndrome.  Special attention to the Microbiome resulted in a “capsule in a capsule” means of delivering live bacteria to the colon, now licensed for use in treating diseases of dysbiosis or disordered signaling. He is also expert in neural net mathematical modeling of disease progression, as the co-inventor of the FS-index, the best available means of the composite measurement of metabolic disease. Together these inventions and discoveries have enabled new approaches in the treatment of metabolic diseases, all of which are increasing in worldwide prevalence.

In addition he first used the SmartPill as a means of studying the oral absorption and intracellular delivery of peptides, proteins and other macromolecules. This led to the discovery of the Chylomicron mechanism of action and several patents of Cholestosomes™, the currently best known oral means of delivering otherwise injectable biologicals.

Dr Schentag obtained his Pharm.D. degree at the Philadelphia College of Pharmacy & Science, followed by a postdoctoral fellowship in Clinical Pharmacokinetics at the State University of NY (SUNY), Buffalo, where he continues to serve as a fellow in the Center for Entrepreneurial Leadership.

Professor Schentag’s entrepreneurial experience comprises several private equity investments and exit transactions across a broad spectrum in healthcare.

Inventions and Patents

Design and management of clinical trials including our own inventions

Mathematical Modeling of Diseases including application development

Consulting on Drug Delivery Methods and Technologies

Current Rank: Emeritus Professor, University at Buffalo NY
(1975-2015)
A 40 year Academic Track; Clinical Teaching, Discovery and clinical applications, primarily in the disciplines of Pharmacokinetics, Pharmacodynamics, Pharmacometrics, with emphasis on Therapeutics for Infectious Diseases, Critical care medicine, Metabolic Diseases, Cardiovascular, and more recently Immuno-oncology. More than 350 publications and many book chapters. See the Google scholar link for current listing of publications, each ranked by numbers of citations

Chief Executive Officer, CPL Associates LLC
(2001 – 2020)
CPL Associates is a specialty Clinical Research Organization, dedicated to high-end disease model design and management of clinical trial data in our specialty focus areas of Drug Delivery, Pharmacometrics, Metabolic Syndrome diseases, and Immuno-oncology. CPL Associates is our operational unit and a partner for Those Challenging Molecules seeking a role in modern Therapeutics

  • Link to CPL Associates Website

Chief Executive Officer, TheraSyn Companies
(2007 – 2020)
TheraSyn companies hold the patents for our Wearable Sensors and Devices, Novel treatments, drug delivery systems, and our Mathematical Models of Disease. Licensing agreements and co-development agreements for these patents are the ongoing business model of the TheraSyn companies